

Arrivo BioVentures to Present Phase 1 qEEG Data at 2025 ASCP Annual Meeting

Data reveal findings about qEEG brain activity associated with Forvisirvat, the company's first-in-class epigenetic oral activator of the SIRT6 enzyme

Forvisirvat has the potential to be the first treatment for females with major depressive disorder

MORRISVILLE, N.C., May 27, 2025 – [Arrivo BioVentures](https://www.arrivobio.com) will present new clinical data at the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 27–30 in Scottsdale, Arizona.

The late-breaking poster provides findings from a Phase 1 study on qEEG-based brain network analytics (BNA) in healthy participants treated with Arrivo's first-in-class epigenetic oral activator of the SIRT6 enzyme, Forvisirvat, with a focus on potential pro-cognitive and antidepressant effects.

Poster Title: The SIRT6 Activator, Forvisirvat (SP-624), Shows Pro-cognitive and Antidepressant Effects on qEEG Brain Analytics: A Phase 1 Study

Poster Session: 1

Poster Number: W41

Presenter: Greg Rigdon, Ph.D.

Date/Time: Wednesday, May 28, from 11:15 a.m. to 1:00 p.m. ET

Location: Palomino Ballroom

For more about Arrivo and Forvisirvat, visit www.arrivobio.com.

About Arrivo BioVentures

Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.

Media Contact:

Alexis Feinberg

Vice President, ICR Healthcare

Alexis.feinberg@icrhealthcare.com